Humacyte, Inc. (NASDAQ:HUMA) Given Consensus Rating of “Buy” by Brokerages

Humacyte, Inc. (NASDAQ:HUMA) has been given a consensus rating of “Buy” by the eight analysts that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation, six have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $13.71.

Several research firms have recently issued reports on HUMA. D. Boral Capital reaffirmed a “buy” rating and set a $25.00 price target on shares of Humacyte in a research note on Tuesday, January 21st. BTIG Research reaffirmed a “buy” rating and set a $10.00 target price on shares of Humacyte in a research report on Friday, October 18th. HC Wainwright reiterated a “buy” rating and issued a $15.00 price target (up previously from $12.00) on shares of Humacyte in a research report on Friday, December 20th. Piper Sandler set a $6.00 price objective on Humacyte and gave the stock a “neutral” rating in a research report on Friday, October 18th. Finally, TD Cowen reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Humacyte in a research note on Friday, October 18th.

Humacyte Trading Down 0.7 %

Shares of HUMA stock opened at $4.27 on Friday. The firm has a market capitalization of $537.42 million, a price-to-earnings ratio of -3.19 and a beta of 1.30. The business’s 50-day moving average price is $4.53 and its 200-day moving average price is $5.46. Humacyte has a 12 month low of $2.81 and a 12 month high of $9.97.

Humacyte (NASDAQ:HUMA) last posted its earnings results on Friday, November 8th. The company reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.08). During the same period last year, the business posted ($0.25) EPS. On average, sell-side analysts predict that Humacyte will post -1.27 earnings per share for the current fiscal year.

Insider Activity at Humacyte

In related news, CEO Laura E. Niklason sold 811,172 shares of the stock in a transaction on Monday, November 18th. The shares were sold at an average price of $4.44, for a total transaction of $3,601,603.68. Following the transaction, the chief executive officer now directly owns 2,419,712 shares of the company’s stock, valued at $10,743,521.28. This represents a 25.11 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Brady W. Dougan sold 427,459 shares of Humacyte stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $4.34, for a total transaction of $1,855,172.06. Following the completion of the sale, the director now directly owns 1,992,253 shares of the company’s stock, valued at approximately $8,646,378.02. This trade represents a 17.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 1,500,000 shares of company stock worth $6,606,799 in the last 90 days. Corporate insiders own 11.20% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. increased its holdings in shares of Humacyte by 18.8% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 27,282 shares of the company’s stock valued at $138,000 after acquiring an additional 4,327 shares in the last quarter. Rhumbline Advisers grew its position in Humacyte by 4.6% in the 4th quarter. Rhumbline Advisers now owns 114,455 shares of the company’s stock valued at $578,000 after purchasing an additional 5,005 shares during the period. Private Advisor Group LLC increased its stake in Humacyte by 1.8% during the 3rd quarter. Private Advisor Group LLC now owns 373,110 shares of the company’s stock valued at $2,030,000 after purchasing an additional 6,510 shares in the last quarter. SG Americas Securities LLC raised its holdings in Humacyte by 22.0% during the fourth quarter. SG Americas Securities LLC now owns 39,143 shares of the company’s stock worth $198,000 after buying an additional 7,069 shares during the last quarter. Finally, The Manufacturers Life Insurance Company lifted its stake in shares of Humacyte by 32.5% in the second quarter. The Manufacturers Life Insurance Company now owns 34,919 shares of the company’s stock valued at $168,000 after buying an additional 8,557 shares in the last quarter. Institutional investors own 44.71% of the company’s stock.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.